인쇄하기
취소

Daewoong and AstraZeneca Korea to co-market Symbicort in Korea

Published: 2011-07-28 06:57:00
Updated: 2011-07-28 06:57:00
Daewoong Pharmaceutical and AstraZeneca Korea (AZK) Monday announced that the two companies have signed an agreement to co-market Symbicort (budesonide/formoterol) in Korea, in addition to Nexium.

Launched in 2001, Symbicort is a combination formulation used in the management of asthma and chronic obstructive pulmonary disease (COPD). The drug has shown some efficacy as a medicine not only u...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.